Blood Cancer News and Research RSS Feed - Blood Cancer News and Research

Scientists elucidate why acute leukemias with same genetic abnormality vary in aggressiveness

Scientists elucidate why acute leukemias with same genetic abnormality vary in aggressiveness

Scientists at the Friedrich Miescher Institute for Biomedical Research and the University of Basel have discovered why acute leukemias with the same genetic abnormality vary in their aggressiveness based on their cellular origin. [More]
Potential therapeutic approaches to combat chronic myeloid leukemia

Potential therapeutic approaches to combat chronic myeloid leukemia

Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type of blood cancer. [More]
PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar announces initiation of pivotal plitidepsin clinical trial in patients with T-cell lymphomas

PharmaMar today announced the start of a multicenter, prospective, pivotal study to analyze the efficacy of the antitumoral compound of marine origin, plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma. [More]
Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

Discovery on new form ETV6-related thrombocytopenia presented at EHA Annual Congress

We recently discovered a new form of an inherited deficiency of platelets, which is caused by mutations in the ETV6-gene. [More]
Researchers discover AF1q protein linked to multiple myeloma, EMD

Researchers discover AF1q protein linked to multiple myeloma, EMD

A group of researchers from the University of Louisville, Japan and Austria is the first to identify a protein, AF1q, associated with multiple myeloma and a condition that occurs in approximately one-fourth of very aggressive multiple myeloma, extramedullary disease or EMD. [More]
Joint research reveals key mechanisms of persistent latent infection of HTLV-1

Joint research reveals key mechanisms of persistent latent infection of HTLV-1

Joint research between scientists from Kumamoto University, Japan and Imperial College London, UK has revealed the mechanisms of persistent latent infection of the human T-cell leukemia virus type 1 (HTLV-1). [More]
Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

An immune-based therapy developed at Roswell Park Cancer Institute is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer. [More]
The National MDS Study aims to identify causes, genetic makeup of fatal blood diseases

The National MDS Study aims to identify causes, genetic makeup of fatal blood diseases

The National Myelodysplastic Syndromes Natural History Study is underway, the ECOG-ACRIN Cancer Research Group and its collaborators announced today. [More]
Sylvester researchers test new KTE-C19 therapy for patients with aggressive non-Hodgkin's lymphoma

Sylvester researchers test new KTE-C19 therapy for patients with aggressive non-Hodgkin's lymphoma

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are testing a novel cellular immunotherapy approach to treating patients with diffuse large B-cell lymphoma who have failed standard therapy. [More]
Phase I study of triple drug combination shows promise in multiple myeloma patients

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. [More]
Novel therapeutic approach to treat leukaemia patients

Novel therapeutic approach to treat leukaemia patients

Cancer cells have an abnormal cell division and survival machinery - they grow faster than they die. For their permanent development, they produce an excess of growth factors and nutrients and block the body's own safety mechanisms. [More]
Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion. [More]
TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

TJP1 protein could help determine multiple myeloma patients who may best benefit from proteasome inhibitors

A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center. [More]
Penn researchers report results of CAR therapy trial in brain cancer patients

Penn researchers report results of CAR therapy trial in brain cancer patients

Immune cells engineered to seek out and attack a type of deadly brain cancer known as glioblastoma (GBM) were found to have an acceptable safety profile and successfully migrate to and infiltrate tumors, researchers from Penn Medicine and Harvard University reported at the AACR Annual Meeting 2016. [More]
CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

CHMP recommends conditional marketing authorisation for Janssen’s daratumumab

Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the granting of a conditional marketing authorisation for first-in-class CD38 immunotherapy daratumumab in the European Union. [More]
Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

Plitidepsin in combination with dexamethasone shows top-line results in Phase III multiple myeloma trial

PharmaMar today announced positive top-line results of its Phase III clinical trial -ADMYRE- with Aplidin (plitidepsin) in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM). [More]
Four key genes govern growth, multiplication of blood stem cells

Four key genes govern growth, multiplication of blood stem cells

An important element in getting blood stem cells to multiply outside the body is to understand which of the approximately 20,000 genes in the human body control their growth. Now a research team at Lund University in Sweden has studied close to 15,000 of these genes alongside each other. [More]
Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Ibrutinib and idelalisib drugs for chronic lymphatic leukaemia can prolong survival time of high-risk patients

Studies conducted at the Comprehensive Cancer Center at MedUni Vienna and Vienna General Hospital show that the drugs ibrutinib and idelalisib used in the targeted treatment of chronic lymphatic leukaemia can significantly prolong the survival time of high-risk patients. [More]
Scientists find surprising link between iPS cell reprogramming, blood cell formation and cancer

Scientists find surprising link between iPS cell reprogramming, blood cell formation and cancer

The ability to reprogram cells has revolutionized stem cell research with major implications for almost all fields of modern biology. A decade ago Shinya Yamanaka described a procedure that revolutionized stem cell biology. Using a genetic trick that introduces a cocktail of four genes into cultured cells from human biopsies, he was able to generate induced pluripotent stem cells (iPS) from mature skin or blood cells [More]
RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

RUVICA (ibrutinib) capsules approved for treatment-naïve CLL patients

The U.S. Food and Drug Administration has approved IMBRUVICA (ibrutinib) capsules for treatment-naïve patients with chronic lymphocytic leukemia (CLL). [More]
Advertisement